Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
107,809,066
-
Total 13F shares
-
16,794,955
-
Share change
-
+62,318
-
Total reported value
-
$268,727,920
-
Put/Call ratio
-
119%
-
Price per share
-
$16.00
-
Number of holders
-
80
-
Value change
-
+$2,720,387
-
Number of buys
-
54
-
Number of sells
-
22
Institutional Holders of Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) as of Q2 2017
As of 30 Jun 2017,
Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) was held by
80 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
16,794,955 shares.
The largest 10 holders included
Atlas Venture Associates IX, LLC, FMR LLC, ORBIMED ADVISORS LLC, BlackRock Inc., BAKER BROS. ADVISORS LP, VANGUARD GROUP INC, Temasek Holdings (Private) Ltd, GRANAHAN INVESTMENT MANAGEMENT INC/MA, Artal Group S.A., and MORGAN STANLEY.
This page lists
81
institutional shareholders reporting positions in this security
for the Q2 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.